Cyclerion Therapeutics Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $5.25 on 12/19/23 and the lowest value was $1.71 on 11/21/24.
52-week price history of CYCN Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Cyclerion Therapeutics Inc’s current trading price is -72.95% away from its 52-week high, while its distance from the 52-week low is -16.96%. The stock’s price range during the 52-week period has remained between $1.71 and $5.25. In the Healthcare sector, the company’s shares saw a trading volume of around 0.69 million for the day, which was evidently higher than the average daily volume of 0.21 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Cyclerion Therapeutics Inc (CYCN) has experienced a quarterly decline of -51.54% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.85M and boasts a workforce of 1 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.78, with a change in price of -0.88. Similarly, Cyclerion Therapeutics Inc recorded 146,502 in trading volume during the last 100 days, posting a change of -38.26%.
Examining CYCN’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for CYCN stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
CYCN Stock Stochastic Average
Cyclerion Therapeutics Inc’s raw stochastic average for the past 50 days is presently 0.00%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 0.00%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 11.16% and 13.41%, respectively.
CYCN Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. This year’s metric has recorded a Price decrease of -57.61%. However, over the past six months, we’ve seen a stronger performance of -50.70%. The price of CYCN leaped by -50.52% over the last 30 days. And in the last five days, it has fallen by -19.77%.
